Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.55 |
| ▸ | PGR | P06401 | 5/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24924163 | 0.88 | NR3C1 (0.60) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL25230008 | 0.83 | NR3C1 (0.57) | NR3C1PGRCYP11B2 | |
| SCHEMBL1542086 | 0.82 | NR3C1 (0.57) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL836599 | 0.82 | NR3C1 (0.55) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL1363835 | 0.82 | NR3C1 (0.57) | NR3C1PGRSMO | |
| SCHEMBL1541841 | 0.82 | ALDH1A1 (0.54) | NR3C1PGRCYP11B2 | |
| SCHEMBL15813253 | 0.79 | NR3C1 (0.52) | NR3C1PGRSMO | |
| SCHEMBL31221968 | 0.79 | NR3C1 (0.52) | NR3C1PGRSMO | |
| SCHEMBL1361803 | 0.79 | NR3C1 (0.52) | NR3C1PGRSMO | |
| SCHEMBL22225746 | 0.78 | NR3C1 (0.74) | NR3C1PGRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-07-03 | — | — | US | disclosed |
| CN-116113627-B | Ji Yin-dole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-04-10 | — | — | US | disclosed |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2025-03-20 | — | — | US | disclosed |
| US-12180186-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4452968-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | Corcept Therapeutics Incorporated (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118715217-A | Piperazine indole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12098144-B2 | Piperazine indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-09-24 | — | — | US | disclosed |
| CN-118660879-A | Bicyclic indole glucocorticoid receptor antagonists | 科赛普特治疗公司 | 2024-09-17 | — | — | CN | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014094357-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014094357-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20110112299-A1 | TETRACYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2308880-A1 | TETRACYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115583-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | NR3C1 1/4885PGR 205/4885CYP11B2 16/4885 |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | NR3C1 6/4885PGR 26/4885CYP11B2 47/4885 |
| US-20250092023-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | NR3C1 1/4885PGR 65/4885CYP11B2 92/4885 |
| US-12180186-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 92/4885CYP11B2 6/4885 |
| US-12098141-B2 | Bicyclic indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR1I2 | NR3C1 1/4885PGR 205/4885CYP11B2 16/4885 |
| US-12098144-B2 | Piperazine indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, NR5A2 | NR3C1 1/4885PGR 66/4885CYP11B2 79/4885 |
| US-20250214971-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 92/4885CYP11B2 6/4885 |
| US-20110112299-A1 | TETRACYCLIC COMPOUND | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, LPXN | NR3C1 236/4885PGR 1128/4885CYP11B2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.